

where

n is [1-]3;

X is either O or S;

R<sub>1</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, or heterocycle;

D is a bond, or a C<sub>1</sub>-C<sub>10</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl or C<sub>2</sub>-C<sub>10</sub> alkynyl;

R<sub>2</sub> is a carboxylic acid or a carboxylic acid isostere; and wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, or carboxylic acid isostere is optionally substituted with one or more substituents selected from R<sup>3</sup> and Z, where

R<sup>3</sup> and Z are independently hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C<sub>1</sub>-C<sub>6</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>6</sub> straight or branched chain alkenyl or alkynyl, aryl, aralkyl, heteroaryl, carbocycle, heterocycle, or CO<sub>2</sub>R<sup>7</sup> where R<sup>7</sup> is hydrogen or C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl


or C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl;

or a pharmaceutically acceptable salt, ester, or solvate thereof[; provided that:

when n=1, and D is a bond, and R<sub>2</sub> is COOH,

then R<sub>1</sub> is not C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl, C<sub>5</sub>-C<sub>7</sub> cycloalkyl, C<sub>5</sub>-C<sub>7</sub> cycloalkenyl, phenylamine, 2-(3,4-dichlorophenyl)ethyl, hydroxy, ethoxy, benzyl, or Ar<sub>1</sub>, where Ar<sub>1</sub> is 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thiazolyl, 2-thienyl, 3-thienyl, 1-pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, and wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar<sub>1</sub> are optionally substituted with one or more substituents selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C<sub>1</sub>-C<sub>9</sub> straight or branched alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched alkenyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>2</sub>-C<sub>4</sub> alkenyloxy, phenoxy, benzyloxy, COOH, and amino; further provided that:

when n=1, and D is a bond, and R<sub>2</sub> is the carboxylic acid isostere -CONZ(R<sup>3</sup>), and Z is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, and R<sup>3</sup> is phenyl, or C<sub>2</sub>-C<sub>6</sub> straight or branched chain alkyl or alkenyl, wherein said alkyl is unsubstituted or substituted in one or more positions with Ar<sub>2</sub> as defined below, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, cycloalkyl connected by methyl or a C<sub>2</sub>-C<sub>6</sub> straight or branched chain alkyl or alkenyl chain, C<sub>1</sub>-C<sub>4</sub> alkyl ester, or Ar<sub>3</sub> where Ar<sub>3</sub> is selected from the group



then R<sub>1</sub> is not C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl, substituted thiophene, or C<sub>1</sub>-C<sub>4</sub> alkoxy, wherein said alkyl or alkenyl is optionally substituted in one or

more positions with C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>5</sub>-C<sub>7</sub> cycloalkenyl, or Ar<sub>2</sub>, where Ar<sub>2</sub> is defined below, where said alkyl, alkenyl, cycloalkyl or cycloalkenyl groups may be optionally substituted with C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkenyl, or hydroxy, and where Ar<sub>2</sub> is 1-naphthyl, 2-naphthyl, 2-indolyl, 3-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or phenyl, having one to three substituents selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub> straight or branched alkyl, C<sub>2</sub>-C<sub>6</sub> straight or branched alkenyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>2</sub>-C<sub>4</sub> alkenyloxy, phenoxy, benzyloxy, and amino;

① further provided that:

when n=1, and X is O, and D is a bond, and R<sub>2</sub> is -CONH<sub>2</sub>, then R<sub>1</sub> is not methyl, ethyl, iso-propyl, iso-butyl, iso-pentyl, 4-methylpentyl, indolyl, phenyl, or hydroxyphenyl;

further provided that:

when n=1, and X is O, and D is a bond, and R<sub>2</sub> is cyano, then R<sub>1</sub> is not methyl;

further provided that:

when n=2, and X is O, and D is a bond, and R<sub>2</sub> is CONZ(R<sup>3</sup>), and R<sub>1</sub> is ethoxy, then R<sup>3</sup> or Z is not halo-substituted phenyl;

further provided that:

when n=2, and X is O, and D is a bond, and R<sub>2</sub> is CONZ(R<sup>3</sup>) and R<sub>1</sub> is substituted thiophene or tetrahydropyranoxy, or methoxy, then R<sup>3</sup> or

Z is not C<sub>1</sub>-C<sub>4</sub> alkyl ester substituted ethyl;

further provided that:

when n=2, and X is O, and D is a bond, and R<sub>2</sub> is CONZ(R<sup>3</sup>) and R<sub>1</sub> is ethoxy, then R<sup>3</sup> or Z is not 4-chlorophenyl;

further provided that:

when n=2, and X is O, and D is a bond, and R<sub>2</sub> is CONZ(R<sup>3</sup>) and R<sub>1</sub> is cyclohexyl, then R<sup>3</sup> or Z is not ethyl or propyl substituted with phenyl;

further provided that:

when D is CH<sub>2</sub>, then R<sub>2</sub> is not -OMe, -NHMe, or substituted -NHcyclohexyl;

further provided that:

when D is CH<sub>2</sub>, and R<sub>2</sub> is -OH,

then R<sub>1</sub> is not phenyl or pyrrolidinemethanol;

further provided that:

when n=2, and X is O, and D is a bond, and R<sub>2</sub> is COOH,

then R<sub>1</sub> is not methyl, tert-butyl, 1,1-dimethyl-2-methyl-propyl, 1,1-dimethyl-propyl, methoxy, ethoxy, phenyl,

tetrahydropyranoxy substituted C<sub>4</sub>-C<sub>6</sub> alkyl, 1-methyl-1-methoxyamide, 1-methylcyclohexyl, 3-iodophenyl, 3-methyl ester-cyclopentyl, 1,1-dimethyl-6-phenyl-hex-3,5-dioxy, or trimethoxyphenyl].

---

5. (Amended) The compounds, [(2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-hydroxymethylpyrrolidine; (2S)-1-(1,2-dioxo-3,3-

22  
A2  
dimethylpentyl)-2-pyrrolidinetetrazole; (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarbonitrile; and (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-aminocarbonyl piperidine; and compounds 1-25, 27, 28, 31-33, and 35-136] 4, 7, 10, 13, 16, 19, 20, 23, and 103-105 of Tables I[, II,] and III.

---

8. (Amended) A pharmaceutical composition, comprising:

- A3
- a) an effective amount of [an N-heterocyclic carboxylic acid or carboxylic acid isostere] the compound of claim 1; and
  - b) a pharmaceutically acceptable carrier.
- 

Claim 10, page 127, line 27, after "The pharmaceutical composition of ~~claim~~" and before ", wherein", please replace "9" with --8--.

Claim 11, page 128, line 6, after "The pharmaceutical composition of ~~claim~~" and before ", wherein", please replace "9" with --8--.

Claim 12, page 129, line 4, after "The pharmaceutical composition of ~~claim~~" and before ", wherein", please replace "9" with --8--.

---

A4

13. (Amended) The pharmaceutical composition of claim [9] 8, wherein the [N-heterocyclic carboxylic acid or carboxylic acid isostere] compound is selected from the group consisting of compounds [1-139] 4, 7, 10, 13, 16, 19, 20, 23, and 103-105.

---

A5

16. (Amended) A method of treating a neurological disorder in